TRIM24 Antibody

Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Liquid

12-14 weeks (made-to-order)

E3 ubiquitin protein ligase TRIM24 antibody; E3 ubiquitin-protein ligase Trim24 antibody; hTIF1 antibody; PTC6 antibody; RING finger protein 82 antibody; RNF82 antibody; TF1A antibody; TIF1 alpha antibody; TIF1 antibody; TIF1-alpha antibody; TIF1A antibody; TIF1A_HUMAN antibody; TIF1ALPHA antibody; Transcription intermediary factor 1-alpha antibody; Transcriptional intermediary factor 1 alpha antibody; Transcriptional intermediary factor 1 antibody; Trim24 antibody; Tripartite motif containing 24 antibody; Tripartite motif-containing protein 24 antibody

TRIM24

O15164

TRIM24 is a transcriptional coactivator that interacts with numerous nuclear receptors and coactivators, modulating the transcription of target genes. Its chromatin interaction is influenced by histone H3 modifications, exhibiting highest affinity for histone H3 that is unmodified at Lysine 4 (H3K4me0) and acetylated at Lysine 23 (H3K23ac). TRIM24 possesses E3 protein-ubiquitin ligase activity, promoting the ubiquitination and subsequent proteasomal degradation of p53/TP53. It plays a crucial role in regulating cell proliferation and apoptosis, at least partially through its effects on p53/TP53 levels. Furthermore, TRIM24 upregulates ligand-dependent transcriptional activation by androgen receptor (AR), glucocorticoid receptor (GR/NR3C1), thyroid hormone receptor (TR), and estrogen receptor alpha (ESR1). Its activity extends to modulating transcriptional activation by retinoic acid (RA) receptors, including RARA, and regulating retinoic acid-dependent hepatocyte proliferation.

• TRIM24 plays a significant role in nasopharyngeal carcinoma (NPC) growth. Its silencing inhibits cell proliferation and induces apoptosis in NPC cells. PMID: 29749443
• Upregulated in head and neck squamous cell carcinoma (HNSCC), TRIM24 promotes cell growth and invasion by modulating cell cycle progression, glucose metabolism, and GLUT3 expression, suggesting its oncogenic potential. PMID: 29862279
• TRIM24 acts as an oncogenic transcriptional coactivator in epidermal growth factor receptor-driven glioblastoma. It mediates epidermal growth factor receptor stimulation of STAT3 activation via H3K23ac, enhancing the oncogenic activity of the EGFR/STAT3 pathway. PMID: 29129908
• TRIM24 functions as a novel coactivator of the constitutive androstane receptor (CAR), involved in cell- and/or promoter-selective transactivation. PMID: 29101097
• Increased TRIM24 expression in human colorectal cancer suggests its potential as a prognostic biomarker. PMID: 28916426
• TRIM24 is upregulated during gastric carcinogenesis and is a functional target gene of miR-511, which inactivates PI3K/AKT and Wnt/β-catenin pathways by suppressing TRIM24. PMID: 28114950
• Altered glucose metabolism in head and neck squamous cell carcinoma is partly attributed to the interaction between GLUT4 and TRIM24. PMID: 28061796
• Reduced TRIM24 protein correlates with poor survival in esophageal squamous cell cancer (ESCC), indicating its potential as a prognostic biomarker. PMID: 27689360
• In cardiomyocytes, TRIM32 attenuates SRF signaling and hypertrophy caused by dysbindin, while TRIM24 promotes these effects. TRIM32 promotes dysbindin degradation, whereas TRIM24 protects it. PMID: 28465353
• A "synergistic modification induced recognition" hypothesis links histone modification and TRIM24 binding. PMID: 27079666
• TRIM24 plays an oncogenic role as a transcriptional activator and mediator of hormone-refractory prostate cancer cell growth in SPOP mutant and castration-resistant prostate cells. PMID: 27238081
• TRIM24 expression correlates positively with acetylated H3 lysine 23 levels; high levels of both predict shorter overall survival in breast cancer patients. PMID: 27638829
• TRIM24 regulates gefitinib resistance via the Akt pathway in non-small cell lung cancer (NSCLC) cells. PMID: 26805734
• Overexpressed in human bladder cancer, TRIM24 facilitates cancer growth and invasion, possibly through NF-κB and AKT signaling pathways. PMID: 25846736
• TRIM24 functions as an oncogene in colorectal carcinogenesis. PMID: 25700357
• TRIM24 contributes to breast tumorigenesis by reprogramming glucose metabolism in human mammary epithelial cells, establishing it as a potential therapeutic target. PMID: 25065590
• TRIM24 overexpression in human gastric cancer accelerates cell growth and induces chemoresistance. PMID: 25724180
• TRIM24 is a potential prognostic marker and therapeutic target for malignant gliomas. PMID: 24469053
• ATM-mediated phosphorylation of TRIM24 at Serine 768 destabilizes it in response to DNA damage, disrupting TRIM24-p53 interactions and promoting TRIM24 degradation. PMID: 24820418
• TRIM24 overexpression is associated with the onset and progression of hepatocellular carcinoma. PMID: 24409330
• TRIM24 silencing inhibits HNSCC cell proliferation by inducing apoptosis. PMID: 23717505
• TRIM24 plays an important role in NSCLC progression. PMID: 22666376
• E4-ORF3 targets proteins for relocalization through a loosely homologous sequence dependent on accessibility. PMID: 22123502
• TRIM24/TIF-1α overexpression in breast cancer is associated with poor prognosis and survival. PMID: 21435435
• Aberrant TRIM24 expression negatively correlates with breast cancer patient survival. PMID: 21164480
• TRIM24 regulates AR-mediated transcription in collaboration with TIP60 and BRD7. PMID: 19909775
• Preferential TRIM24 (HTIF1α) expression in acute myeloid leukemia (AML) and MDS-related AML suggests a role in myeloid differentiation. PMID: 11986951
• TRIM24 interacts with TIF1γ, and the coiled-coil region of TIF1γ is necessary for this interaction. PMID: 12096914
• ZCCHC11, a TLR signal regulator, interacts with TIFA after LPS treatment and suppresses TRAF6-dependent NF-κB activation. PMID: 16643855
• An interaction between E4 ORF3 and TRIM24 has been identified. PMID: 17287283

HGNC: 11812

OMIM: 603406

KEGG: hsa:8805

STRING: 9606.ENSP00000340507

UniGene: Hs.490287

A chromosomal aberration involving TRIM24/TIF1 is found in papillary thyroid carcinomas (PTCs). Translocation t(7;10)(q32;q11) with RET. The translocation generates the TRIM24/RET (PTC6) oncogene.

Nucleus. Cytoplasm. Note=Colocalizes with sites of active transcription. Detected both in nucleus and cytoplasm in some breast cancer samples. Predominantly nuclear.